MannKind denies misconduct of Afrezza clinical trials in Russia and Bulgaria
This article was originally published in Scrip
Executive Summary
MannKind, the US company focusing on R&D and commercialisation of diabetes and cancer treatments, has denied that clinical trials of Afrezza, its diabetes drug candidate, in Russia and Bulgaria did not comply with standards. The misconduct allegations were made by John Arditi, a former regulatory affairs executive, who is suing MannKind for wrongful termination of his employment.